In the weeks before the final vote in the Scottish Parliament on Liam McArthur MSP’s Assisted Dying for Terminally Ill Adults (Scotland) Bill, new findings from the British Social Attitudes Survey show that an overwhelming majority of Scots (81%) support assisted dying for terminally ill people.
The report notes that the public has long been in support of a change in the law, and that this support remains unchanged despite the intensive debate regarding the issue over the last year.
Ally Thomson, Director of Dignity in Dying Scotland, said: “These findings are a powerful reminder that the Scottish public has long supported giving dying people the choice and control they desperately need, and that this support has not wavered despite intense scrutiny and debate.
“Without a change in the law terminally ill Scots facing a bad death are forced to contemplate a series of desperate decisions, from trying to go to Switzerland, stopping eating and drinking, taking matters into their own hands in lonely and often brutal ways, or suffering against their will. The most dangerous thing the Parliament can do here is nothing and allow this situation to persist.
“When MSPs voted in favour of Liam McArthur’s Assisted Dying Bill at Stage 1 last year, they gave dying Scots and those who had watched a loved one suffer real hope that such suffering will be consigned to the past.
“It’s clear that the public expect the Scottish Parliament to deliver on this issue and pass the Bill next month.”
Emma Cooper, Convenor, Friends at the End (FATE) said: ““It is very clear that there is sustained, overwhelming public support from Scottish people for assisted dying to be introduced in Scotland.
“No one should have to endure a bad death because the law has failed to provide a compassionate choice.
“Too many people have suffered and seen loved ones suffer unnecessarily.
“MSPs should listen to the will of the people and pass this deeply considered and highly safeguarded legislation, rather than listening to misleading information perpetuated by a few loud and misrepresentative voices.”
TWO directors who lead the Specsavers Home Visits team across Edinburgh, the Lothians and the Scottish Borders both celebrate major career milestones this year, marking a cumulative 35 years with Specsavers caring for the eyesight of local communities across Scotland.
Home Visits partner Lynne Seebaluck began her optical career as an optical assistant for Specsavers in East Kilbride, qualifying as a dispensing optician before moving to the Specsavers store in Bellshill as a retail manager.
At the store, Lynne completed an ILM management course, as well as her Hearing Aid Audiology diploma, moving onto an audiology role as well as store manager.
Lynne became a partner at the Edinburgh Home Visits team in 2022 and brought her experiences, particularly in audiology, to the team – mentoring several team members through their own audiology qualifications.
Reflecting on the past 20 years, Lynne says: ‘I have had such a varied career with Specsavers and there are so many people to thank for making my career such a rewarding one.
“From the directors I’ve worked for over the years, to the great teams I have worked with, even my husband David, who also works for Specsavers.
‘Since I joined as the partner for the Home Visits team, it’s been incredible being able to pay a visit to so many amazing customers. They are so grateful for the service, and they always have super stories to share.
“I’d also like to thank our incredible team of opticians, optical assistants, dispensing opticians, schedulers and audiologists. All of them are amazing and help us to provide the best care to the communities we work in.’
Fellow partner Laura Owens also marks a milestone of 15 years, starting her Specsavers career in a frontline customer service role before progressing through roles such as optical assistant and into a variety of leadership and managements positions.
She joined the Home Visits team back in 2022 and now serves as customer service director for the business, with a strong focus on team wellbeing and patient care at the heart of her day-to-day.
Laura says: ‘My journey with Specsavers has been both rewarding and transformative. I love that we’re not just delivering eye care and audiology services, we’re making a real difference in people’s lives and delivering total care, especially in the home visits space where many of our patients are vulnerable or isolated.
‘Hitting this milestone, I’m also very excited about continuing to shape the future of our Home Visits team. My focus is on driving awareness and making eye and ear care more accessible to those who need it, while ensuring our teams feel supported and empowered.
She adds: ‘I’d like to thank my incredible team both past and present for their dedication, resilience, and heart. Every success we’ve had is a reflection of their hard work and compassion. It’s truly a privilege to be part of a business that truly puts people first.’
The Eric Liddell Community’s manifesto sets out five crucial priorities to support the estimated 90,000 people living with dementia in Scotland
Edinburgh based care and specialist dementia charity, The Eric Liddell Community, has launched its 2026 Manifesto, ‘Priorities and evidence-based recommendations for the next Scottish Parliament’, setting out five urgent priorities to better support people living with dementia, unpaid carers, volunteers, and the communities that rely on them.
With an estimated 90,000 people living with dementia in Scotland, The Eric Liddell Community says the gap between the vision and commitments made in policy are very different from reality. There are rising costs, reduced statutory funding and an increase in demand for these services due to an ageing population, putting immense pressure on charities.
Founded over 45 years ago, The Eric Liddell Community has long supported people living with dementia and their carers, and is now calling on political parties, candidates and policymakers to recognise voluntary organisations as essential partners in addressing societal challenges and delivering services that communities rely on.
“We ask to be recognised, not as a ‘nice to have’, but as a lifeline for many.”
Irene Adams OBE, Chair of The Eric Liddell Community, comments:“Every day we see the difference that care, compassion, and community make to people living with dementia and also to the unpaid carers volunteering their time.
“This means we also see the consequences when we are underfunded and under supported. We urge all Scottish parties to listen to their communities and work with the third sector by turning policy into reality for people who most need the support.”
While Scotland is recognised for its progression with dementia policy, The Eric Liddell Community states that not enough people are able to access these dementia services and support. In addition, 37% of the Scottish adult population (1.7 million people) have provided unpaid care at some point in their lives. The value of this support totals £15.9 billion each year.
The manifesto is built upon 5 urgent priorities for the next Scottish Government, turn policy dementia into reality, take immediate action to address the third sector funding crisis, deliver unpaid carers a legal right to breaks in practice, ensure social care reform improves real experiences and value the importance of volunteers.
To read the full Eric Liddell Community Manifesto for 2026, please visit:Manifesto.
John MacMillan MBE, CEO of The Eric Liddell Community, added:“Our work shows the powerful impact that care and strong community support can make on the growing dementia challenge in Scotland.
“We see the real struggle caused by underfunding and lack of support and hope the Scottish parties will work with the third sector to deliver support where it is most needed.”
The Eric Liddell Community supports thousands of people each year with befriending services, carer’s programmes and a community filled with volunteer-led activities. Their mission is to bring people together in their local communities and have a positive impact on their lives.
To find out more about The Eric Liddell Community please visit: ericliddell.org
Work on safety measures at the Queen Elizabeth University Hospital (QEUH) and the Royal Hospital for Children (RHC) will be monitored by a new group made up of key infection control experts, whistleblowers and patients.
The move was announced by Health Secretary Neil Gray following evidence heard during the Scottish Hospitals Inquiry, which was set up after a number of deaths and high levels of infection at the hospital prompted concerns about patient safety.
The Group will be co-chaired by Sir Lewis Ritchie – the Sir James Mackenzie Professor of General Practice at the University of Aberdeen – and Professor Jann Gardner, Chief Executive of NHS Greater Glasgow and Clyde.
During his statement, the Health Secretary made clear that the work of this Group will not interfere with Lord Brodie’s independent inquiry and will make use of external independent scrutiny from Healthcare Improvement Scotland and NHS Assure. Lord Brodie is expected to deliver his report later this year.
Mr Gray has also confirmed that all material relevant to the Inquiry was provided.
Mr Gray said: “I want to again recognise the profound distress experienced by patients, by grieving families, and by staff who have been impacted by the Scottish Hospitals Inquiry.
“For many, the recent Inquiry hearings looking into the evidence relating to the Queen Elizabeth University Hospital, have reopened longstanding and deeply painful wounds. My thoughts remain with all those affected.
“Our priority is to ensure that patients, families, staff and the public have full confidence in the safety of facilities and the environment in which services are delivered within the QEUH and RHC today.
“NHS Greater Glasgow and Clyde will, from today, establish a high‑level Safety and Public Confidence Oversight Group which will be co-chaired by Sir Lewis Ritchie – who has a very strong reputation in providing external leadership and scrutiny across the NHS – and the Chief Executive of NHS Greater Glasgow and Clyde Professor Jann Gardener.
“The Group will also stand ready to implement the findings from the Scottish Hospitals Inquiry. Enhanced reporting will be established with the Scottish Government who will provide scrutiny, challenge and support to the delivery of NHS GGC’s programme of work.
“All material relevant to the Inquiry has been preserved and submitted as evidence. Scottish Government officials are now examining how the documents referred to by the motion voted on by Parliament can be released safely and lawfully.
“This will see NHS Greater Glasgow and Clyde taking significant, immediate steps to strengthen public confidence in the safety of the Queen Elizabeth University Hospital and Royal Hospital for Children.”
Patients will receive faster diagnosis, quicker treatment, and the support to live well with cancer under the UK government’s landmark new National Cancer Plan
NATIONAL CANCER PLAN FOR ENGLAND
75% of patients diagnosed from 2035 will be cancer-free or living well after five years, following record investment in the NHS
NHS to meet all cancer waiting time standards by 2029, with hundreds of thousands more patients treated within 62 days
Major expansion of robot-assisted surgery and faster diagnostics to slash delays Patients will receive faster diagnosis, quicker treatment, and the support to live well with cancer under the government’s landmark National Cancer Plan, unveiled today.
For the first time, the NHS will commit to ensuring three in four people diagnosed with cancer from 2035 onwards are cancer-free or living well after five years.
This represents the fastest rate of improvement in cancer outcomes this century and will translate to 320,000 more lives saved over the lifetime of the plan.
The NHS has not met its central cancer performance target - that 85% of patients start treatment within 62 days of referral - since 2014. Survival rates are below Romania and Poland for some cancer types.
Under this plan, that will change – by March 2029, the NHS will meet all three cancer waiting time standards, meaning hundreds of thousands more patients will receive timely treatment. This demonstrates the real change being delivered by the government’s record investment as we rebuild the NHS.
60% of patients currently survive for 5 years or more and around 2.4m people are currently living after a cancer diagnosis.
Health and Social Care Secretary Wes Streeting said: “Cancer survival shouldn’t come down to who won the lottery of life. But cancer is more likely to be a death sentence in Britain than other countries around the world.
As a cancer survivor who owes my life to the NHS, I owe it to future patients to make sure they receive the same outstanding care I did.
Thanks to the revolution in medical science and technology, we have the opportunity to transform the life chances of cancer patients. Our cancer plan will invest in and modernise the NHS, so that opportunity can be seized and our ambitions realised.
This plan will slash waits, invest in cutting-edge technology, and give every patient the best possible chance of beating cancer.
Professor Peter Johnson, NHS national clinical director for cancer, said: “Almost everyone will know someone who has been affected by cancer – a friend, a partner, a parent or a child – and for many people it will be part of their own story too.
“This plan sets a clear roadmap for the NHS to diagnose more cancers earlier, ensure more patients are treated on time and improve survival, so that hundreds of thousands more people live longer, healthier lives with or after cancer over the next decade.
“This is alongside delivering the latest breakthroughs in cancer treatment and care to every corner of the country, improving access to pioneering trials and ensuring there is wraparound support for people closer to home.
“The National Cancer Plan will see the NHS deliver world-class cancer care, offering renewed hope for millions and ensuring the health service is there for patients whenever they need it.”
Gemma Peters, Chief Executive at Macmillan Cancer Support, said: “It’s encouraging to see such bold survival ambitions in the National Cancer Plan for England.
“This comes at a time when people living with cancer tell us all too often that their care hasn’t been good enough, from long waits for tests and treatment to being left without the support they need once treatment ends.
“This Plan has the potential to transform care for people living with cancer, ensuring people not only live longer but live better with their diagnosis. We look forward to working with the government to make this vision a reality: adding life to years, as well as years to life.”
Michelle Mitchell, chief executive of Cancer Research UK, said: “The publication of the National Cancer Plan for England represents a significant commitment by the UK government to treat cancer with the seriousness it deserves.
“Across England, too many cancer patients are waiting too long to start treatment, so it’s important that the UK government has committed to meeting cancer waiting time targets by 2029. A wide range of measures will be needed for these to be met.
“In addition to this, it’s promising to see the government’s ambitious commitment to saving more lives from cancer. England lags behind comparable countries on cancer survival and it’s vital that this changes, so more people affected by cancer can live longer, better lives.”
Chris Walden, Chief Executive Officer, Cancer52, said: “For the first time, an England cancer plan includes a specific focus on rare and less common cancers.
“This is a step change; the needs of our community have been heard. We welcome the government’s response to our calls to switch gear on improving diagnosis, increasing research and introducing leadership so that rare and less common cancers have parity.
“Now the changes outlined in the Plan, and the Rare Cancers Bill, have to be implemented in full. They have the potential to make a real difference to the lives of people living with a rare and less common cancer now and in the future.”
Dame Laura Lee, chief executive of Maggie’s, said: “If we are to usher in a new era of world-leading cancer care that is truly catered to the needs of people with cancer, it is vital that the right practical and emotional support is provided to help people manage and live with cancer.
“That’s why we are really pleased to see the government recognise the need to improve support for people at every stage of cancer and acknowledge that the challenges of cancer don’t end when treatment ends.
“We warmly welcome the introduction of the new target and look forward to working with the government and the NHS to ensure people can live well with cancer.
“At Maggie’s, we believe that with the right support, people can live full, productive lives with and beyond cancer. While the number of people diagnosed cancer is only going to rise, more people are surviving than ever before or living for many years as medical advancements effectively keeping cancer at bay.”
The plan sets out sweeping reforms to how cancer is diagnosed and treated:
Faster diagnostics: A £2.3 billion investment will deliver 9.5 million additional tests by 2029 -investing in more scanners, digital technology and automated testing. Where possible, Community Diagnostic Centres will operate 12 hours a day, seven days a week, bringing testing closer to where people live.
Robot-assisted surgery: From hip replacements to heart surgery and cancer operations, the number of robot-assisted procedures will increase from 70,000 to half a million by 2035, reducing complications and freeing up hospital beds.
Treatment at specialist centres: More patients with rarer cancers will have their care reviewed and treated at specialist cancer centres, where they can benefit from the expertise of the best cancer doctors. These centres bring together surgeons, oncologists, specialist nurses and radiologists to agree the best treatment plan for each case.
Genomic testing: Every patient who could benefit will be offered a test that analyses the DNA of their cancer. This helps doctors understand exactly the type of cancer someone has and choose treatments most likely to work for them.
Waiting lists: New technology is being developed to give patients better access to tests for cancer by offering them the earliest available appointment from a range of NHS organisations in their local area.
The UK government has also announced a new AI pilot to help detect hard-to-reach lung cancers sooner with fewer invasive tests as well as a new employer partnership to support England’s 830,000 working-age cancer patients to remain in employment during and after treatment.
While more people survive cancer than ever before, progress has slowed over the last decade, and England remains behind other comparable countries including Australia and Denmark. For some cancers, such as brain cancer, survival rates in England trail behind countries like Croatia and Romania.
The cancer plan comes as the government continues to make strides on cancer waiting lists, diagnosing or ruling out cancer on time for 213,000 extra cases since July last year.
One hundred and seventy community diagnostic centres are now open – with over 100 of them available at evenings and weekends – bringing checks, scans and tests closer to where people live and at times that work around them.
The UK government is also taking tough action on the causes on cancer: introducing a generational ban on smoking and a ban on junk food ads before 9pm.
Up to £20 million made available to boards to boost progress
Waiting lists continue to fall in Scotland with waits over 52 weeks reducing for 7 months in a row.
New figures from Public Health Scotland show at 31 December 2025 new outpatient waits of more than 52 weeks had reduced by 15.4% when compared to November 2025. These waits have reduced every month since July 2025 with total waits over 52 weeks down by 40.1% in that period.
The data also shows long waits for inpatient and daycase procedures have fallen every month since July 2025, with 52 week waits decreasing by 23.9% in that period.
New operation statistics also show an increase in activity in the last year – between January 2025 and December 2025 the number of operations carried out increased by 5.6% compared to the same period the year before. A total of 274,638 procedures were carried out in this period.
To further build on this progress, extra funding of up to £20 million is being made available to health boards for the current year.
Health Secretary Neil Gray said: “These latest figures show our plan is delivering for the people of Scotland and our NHS has turned a corner – we are seeing sustained progress in reducing waiting times with activity also increasing compared to last year.
“Thousands more appointments, operations and procedures are being delivered this year and we are determined to continue to build on this momentum, ensuring people receive the treatment they need as soon as possible.
“We are seeing downward trends across nearly all waiting list indicators which shows our targeted investment this year is having a real impact on people’s lives. None of this would be possible without out hard-working NHS staff and I want to thank each and every one of them for the progress they are delivering.”
The Health, Social Care and Sport Committee published its report today into Attention Deficit and Hyperactivity Disorder (ADHD) and autism pathways and support.
The Committee calls for urgent action to deliver a national plan that ensures autistic people and people with ADHD can access clear, consistent pathways to support across every health board in Scotland.
The Committee welcomes the Scottish Government’s commitment to accept the recommendations in the National Autism Implementation Team (NAIT) Adult Neurodevelopmental Pathways report.
It also notes the Scottish Government’s intention to review implementation of the National Neurodevelopmental Specification for Children and Young People through its new task force.
The Committee expresses concern that many people wait years for neurodevelopmental assessments and that some health board areas have closed waiting lists. It emphasises that long waits harm individuals and may prevent people from making a full contribution to society.
The unprecedented demand for neurodevelopmental assessment is recognised by the Committee and the need to put certain thresholds in place before a referral is made. But the Committee warns that this approach can be seen as gatekeeping and can cause delays to accessing assessments and support.
The report further highlights evidence that long waiting times can push people into crisis, which can increase complexity of the support needed and put additional pressure on services. It calls on the Scottish Government to work with health boards to deliver a shift towards early, progressive support, in line with the principles of the Population Health Framework.
The Committee also heard evidence that long NHS waiting times can push people towards private diagnosis at significant cost, risking a two-tier system.
The Committee calls for a comprehensive review of assessment processes across all areas, leading to a National Standard that guarantees consistency, responsiveness and support across Scotland.
Given current waiting times, the Committee calls for consistent high-quality communication with people on waiting lists, including accurate, supportive, up-to-date and neuro-affirming information that meets the needs of each individual.
Countering claims that neurodevelopmental conditions are subject to over-diagnosis, the report instead notes evidence that rising demand for assessments reflects historic under-diagnosis and improved understanding of these conditions. The report recognises that diagnosis can validate lived experience and help people access adjustments, support and medication if needed.
While the Committee welcomes the Scottish Government’s commitment that diagnosis should not be a prerequisite for support, it remains concerned that, for many individuals, the lack of a formal diagnosis can create a barrier to accessing support. The Committee calls on the Scottish Government to set out actions to prevent diagnosis status becoming an artificial barrier to receiving support.
To improve fairness and consistency, the Committee calls for a plan to deliver mandatory training for everyone involved in making referrals to neurodevelopmental pathways and all health and social care staff in patient-facing roles.
The Committee supports a whole systems approach across health, social care, education and other sectors to improve awareness, reduce stigma and strengthen support for those with neurodevelopmental conditions.
It calls on the Scottish Government to set out what it is doing to advance whole society action, including workforce planning, funding distribution that supports integration, inclusive education, support for families with multiple neurodivergent members, and stronger collaboration across public services.
On publication of the report, Clare Haughey MSP, Convener of the Health, Social Care and Sport Committee said:“Our inquiry has shone a light on the myriad issues those with neurodevelopmental conditions face in accessing and receiving support from Scotland’s NHS.
“We acknowledge the huge rise in demand for assessment and diagnosis and the huge pressure this places on services. But we are concerned that inconsistent care pathways and a lack of support can leave some feeling isolated and unable to access the support they need.
“We are concerned to have heard evidence of long waits for assessments or closed waiting lists, meaning some individuals are unable to access support due to where they live or because they haven’t been diagnosed with a neurodevelopmental condition. It’s clear things need to improve.
“We’re calling for urgent delivery of a national plan so that autistic people and/or people with ADHD are able to access clear, consistent pathways to support regardless of where they live in Scotland.
“We’re also calling on the Scottish Government and health boards to work together to undertake a comprehensive review of the assessment process in order to introduce a National Standard for assessments that guarantees consistency and quality of access throughout Scotland.
“Our Committee wants to see a whole systems and whole society approach to ensure autistic people and/or people with ADHD can access equitable and timely pathways to assessment, treatment and support across Scotland.
“Thank you to all of the individuals who shared their personal experiences of ADHD and autism with us and helped inform our inquiry.”
Other findings in the report:
The report also stresses the need for consistent national data on referrals and waiting times. The Committee calls for steps to enable routine quarterly reporting of data on referrals and waiting times for autism and ADHD, underpinned by national guidance, and for longer-term work to culminate in a comprehensive dashboard.
The Committee pays tribute to third sector organisations that support people who have not received, or are waiting for, diagnosis. It welcomes ongoing commitments such as the Autistic Adult Support Fund and calls for clearer plans to place third sector funding on a sustainable long-term footing.
Both ADHD and autism are neurodevelopmental conditions.
ADHD is characterised by a group of symptoms that includes difficulty in concentrating, hyperactivity and impulsive behaviour. It affects around 5% of school-aged children, and between 2.5% and 4% of adults.
Autism Spectrum Disorder (ASD) is a lifelong developmental condition that affects the way a person communicates, interacts and processes information.
It is often characterised by social and communication difficulties and by repetitive behaviours. Current estimates indicate about 1 in 34 people are autistic, just under 3% of the population.
Endowed Chair of Rheumatology retires from University of Edinburgh
Professor Stuart Ralston retired from his position as Arthritis UK’s Endowed Chair of Rheumatology at the University of Edinburgh and a Festschrift event was held in his honour (January 29).
Professor Ralston has had a decorated career in rheumatology, including holding the position as Arthritis UK’s Endowed Chair for over 20 years. His research focused on the management of bone and joint disease, with a special interest in Paget’s disease.
Professor Ralston’s research has benefitted patients and influenced policy. His medical education contributions have benefitted students globally and his contribution to medicines regulation has saved many lives, notably through his oversight of emergency approval of COVID-19 vaccines as chair of the Commission on Human Medicines.
He was recently (December 2025) duly recognised for these contributions by being awarded the Royal Society of Edinburgh Sir James Black Medal.
Professor Ralston said: “A highlight of my career has been the work in Paget’s disease of the bone, looking at the genetic basis of the condition and doing clinical trials to establish optimal treatment strategies.
“I’ve also enjoyed bringing in new people and seeing them make their own way over the years. It’s been a privilege. I have been lucky to reach the top of my profession.
“While I will be sad to leave, I have still got some outstanding projects to finish off during my retirement and am looking forward to having more time to spend with my family and friends.”
To commemorate his achievements Professor Ralston attended a Festschrift event, where his closest colleagues and collaborators gathered to share warm remarks and celebrate his contributions to the field.
Arthritis UK’s Head of Research Strategy, Sarah Rudkin, attended the event and said: “Professor Ralston has led the field on the molecular and genetic basis of osteoporosis and Paget’s disease for the benefit of people living with these conditions.
“We greatly value his long-standing relationship with Arthritis UK and the varied contributions that he has made to the work of the charity. It’s been a privilege to support him throughout his professional endeavours, and we wish him a joyful retirement.”
Professor Cosimo de Bari, specialist in osteoarthritis and stem cell therapies, has been appointed the new Arthritis UK Endowed Chair of Rheumatology.
Deborah Alsina MBE, Arthritis UK Chief Executive, said: “The position of Endowed Chair at Edinburgh was established to create a nucleus for rheumatology research.
“Professor Ralston’s work has been a testament to our joint commitment to expanding knowledge, improving practice and bettering the lives of those who live who live with these often-debilitating conditions.
“It has been an honour to endorse his successes from his pivotal research developments and clinical trials to his PhD mentorships. He has truly been instrumental in defining the contemporary landscape of rheumatology.
“We are delighted to welcome Professor Cosimo de Bari to this prestigious position and are eager to support him as we journey together towards a cure.”
Professor David Argyle, Head of the College of Medicine and Veterinary Medicine, University of Edinburgh, said: “Established nearly 50 years ago, the Endowed Chair recognises the University’s long-standing excellence in the field of rheumatology.
“Professor Ralston has been central to this endeavour, advancing research to improve patient outcomes worldwide.
“As we celebrate his achievements and bid him a congratulatory farewell, we are equally thrilled to welcome Professor Cosimo de Bari to the position, and look forward to continuing our valued partnership with Arthritis UK to champion innovative research.”
The first patient in Scotland recruited to a major research study has described it as “the light at the end of the tunnel” after he was diagnosed with late-stage lung cancer last year.
The TOURIST PRINCE trial is part of the world’s largest clinical trial using radiotherapy in the treatment of metastatic lung cancer, funded by a £3.4m grant from the National Institute for Health and Care Research (NIHR).
The trial is looking at whether modern radiotherapy treatments can improve outcomes for patients with stage IV disease, who often have a poor prognosis and typically have about a year to live.
PRINCE is part of the wider TOURIST trial platform which is sponsored by The Christie NHS Foundation Trust in Manchester and managed by Southampton Clinical Trials Unit.
81-year-old great-grandfather Robert Brown, a retired managing director from Glasgow, was diagnosed with non-small cell lung cancer (NSCLC) in the summer of 2025. He said: “At the beginning of July, I had a cough which lasted for six weeks before I went to see the GP. He jumped on it right away and sent me for an X-ray at the New Victoria Hospital and it was then that I was diagnosed with lung cancer.
“I’ve had a decent life and lived pretty healthily for 81 years, so I suppose it’s just life, isn’t it? But when the team at the hospital told me about the trial and asked if I’d consider taking part, I went straight on to it. It’s the light at the end of the tunnel.”
Lung cancer is the 3rd most common cancer in the UK, but is the biggest cancer killer, accounting for 21% of cancer deaths annually.
Between 85 and 90 per cent of cases diagnosed are non-small cell lung cancer (NSCLC) and nearly half of these cancers are diagnosed at a late stage when the disease has spread and is incurable, meaning treatment focuses on controlling symptoms and extending life, rather than curing patients.
TOURIST is the first trial in 20 years to look at how radiotherapy could benefit late-stage metastatic lung cancer patients.
It uses a technique called ‘VMAT’ (volumetric modulated arc therapy) which is a form of radiotherapy that uses multiple beams of varying strengths to treat cancer. A device called a linear accelerator (LINAC) delivers high-energy beams while rotating around the patient to treat the tumours.
Professor Matthew Hatton, Honorary Professor of Clinical Oncology at The University of Sheffield, who is the chief investigator for the TOURIST PRINCE trial, said: “Giving the radiotherapy in this way makes it very accurate, shortens the treatment time, and uses a lower overall dose of radiation.
“It means more cancer cells can be killed while also sparing healthy tissue around the organ. Previously this machine has only been used to treat patients with early-stage cancer that has not spread, but we are hoping to show that it could also have benefits for those with late-stage disease. If successful, this trial could change global clinical practice for treating advanced lung cancer.”
Robert, who has been married to his wife Caroline for 56 years and has two children, two grandchildren and two great grandchildren, said: “Being on the trial has been okay for me, I’ve had no issues so far.
“I am still keeping myself fit and strong, and despite my treatment I’m even continuing to go jogging. It feels good to be part of the trial and part of research. Research has got to help.”
The PRINCE trial is aiming to recruit 472 patients newly diagnosed with stage IV non-small cell lung cancer at hospitals across the UK. It first opened to recruitment in autumn 2024, but Robert is the first patient in Scotland to take part.
Lucy Badesha is a Senior Research Nurse at the New Victoria Hospital in Glasgow. She said: “As a satellite site of the Beatson West of Scotland Cancer Centre, part of our mission at the New Victoria Hospital is to offer clinical trials to patients who may not be able to access them otherwise.
“We were delighted to hear that we had recruited the first TOURIST PRINCE participant in Scotland, and we hope to be able to continue to offer participation in this and other life-changing cancer clinical trials to patients living on the south side of Glasgow.”
PRINCE is one of two trials currently recruiting patients in the TOURIST platform, which has been set up to see if radiotherapy, alongside other treatments, improves outcomes and quality of life for lung cancer patients.
Nicky Downs, Senior Trial Manager for the TOURIST trial platform at the Southampton Clinical Trials Unit, said: “It is wonderful to see the first patient recruited to the PRINCE trial in Scotland, and we are so grateful to Robert, and to all the other patients who have agreed to take part in TOURIST, for helping further our research into this awful disease.
“We hope to be able to expand the platform in the coming months with new trials, allowing us to include even more patients, understand the disease better, and learn how we can control patients’ symptoms and improve survival.”
Dr David Woolf, consultant oncologist at The Christie and is the joint chief investigator for the TOURIST platform, said: “The TOURIST trials represent a huge shift in the way we potentially treat lung cancer patients and could bring additional benefit to patients undergoing their standard treatments in the future.
“This is the first time we have delivered a trial in radiotherapy for stage IV NSCLC patients for two decades and techniques have advanced massively in that time. We therefore hope to provide enough evidence to change clinical practice globally, which could help up to a million people a year worldwide.”
Professor Anthony Gordon, Director of NIHR’s Health Technology Assessment Programme, said: “Living with late-stage lung cancer is difficult and challenging for patients and their families.
“This important trial demonstrates innovation by harnessing the latest radiotherapy treatments aiming to improve care for people with this disease to help ease their symptoms and improve outcomes and life expectancy.
“This trial demonstrates NIHR’s mission to drive life-changing research for the health and wealth of our society and ensuring more people can get involved in research. Our aim is to help new treatments reach patients earlier, helping them lead healthier and happier lives, while reducing the burden on the NHS.”
